Evaluation and treatment of the patient coinfected with hepatitis B and HIV

Current HIV/AIDS Reports

Volumn 5, Issue 3, 2008, Pages 103-111

  Kitchell, Ellen ^a   Jain, Mamta K ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; ALPHA2B INTERFERON; EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENTECAVIR; HEPATITIS A HEPATITIS B VACCINE; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; PEGINTERFERON; PEGINTERFERON ALPHA2A; RECOMBINANT HEPATITIS B VACCINE; TELBIVUDINE; TENOFOVIR; VIRUS DNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIVIRUS AGENT;

ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOPENIA; DEPRESSION; DIARRHEA; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; FANCONI RENOTUBULAR SYNDROME; FATIGUE; FLU LIKE SYNDROME; GENOTYPE; HEADACHE; HEPATITIS B; HEPATITIS B VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INFECTION PREVENTION; LACTIC ACIDOSIS; LIVER BIOPSY; MIXED INFECTION; MONOTHERAPY; MYOPATHY; NAUSEA; NEPHROTOXICITY; RASH; RECOMMENDED DRUG DOSE; SIDE EFFECT; STEATOSIS; THYROID DISEASE; TREATMENT DURATION; TREATMENT RESPONSE; URINARY TRACT INFECTION; VACCINATION; VOMITING; DRUG COMBINATION; REVIEW;

ANTI-HIV AGENTS; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS B; HIV INFECTIONS; HUMANS;

EID: 48949102249     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-008-0017-1     Document Type: Article

References (50)

1. Thio CL, Seaberg EC, Skolasky R Jr, et al.: HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002, 360:1921-1926.
2. Di Martino V, Thevenot T, Colin JF, et al.: Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Gastroenterology 2002, 123:1812-1822.
3. Iloeje UH, Yang HI, Su J, et al.: Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006, 130:678-686.
4. Bonacini M, Louie S, Bzowej N, Wohl AR: Survival in patients with HIV infection and viral hepatitis B or C: a cohort study. AIDS 2004, 18:2039-2045.
5. Osborn MK, Guest JL, Rimland D: Hepatitis B virus and HIV coinfection: relationship of different serological patterns to survival and liver disease. HIV Med 2007, 8:271-279.
6. Gandhi RT, Wurcel A, Lee H, et al.: Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen: implications for hepatitis B vaccine strategies. J Infect Dis 2005, 191:1435-1441.
7. Seremba E, Joshi R, Attar N, et al: Liver disease progression among HIV-infccted patients with viral hepatitis [abstract]. Presented at the 58th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA; November 2-6, 2007.
8. Soriano V, Barreiro P, Martin-Carbonero L, et al.: Treatment of chronic hepatitis B or C in HIV-infected patients with dual viral hepatitis. J Infect Dis 2007, 195:1181-1183.
9. Chan HL, Hui AY, Wong ML, et al.: Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut 2004, 53:1494-1498.
10. Flink HJ, van Zonneveld M, Hansen BE, et al.: Treatment with peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol 2006, 101:297-303.
11. Jain MK, Comanor L, White C, et al.: Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response. J Viral Hepat 2007, 14:176-182.
12. Chu CJ, Keeffe EB, Han SH, et al.: Hepatitis B virus genotypes in the United States: results of a nationwide study. Gastroenterology 2003, 125:444-451.
13. Lacombe K, Massari V, Girard PM, et al.: Major role of hepatitis B genotypes in liver fibrosis during coinfection with HIV. AIDS 2006, 20:419-427.
14. Mommeja-Marin H, Mondou E, Blum MR, Rousseau F: Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology 2003, 37:1309-1319.
15. Schmutz G, Nelson M, Lutz T, et al.: Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. AIDS 2006, 20:1951-1954.
16. McMahon MA, Jilek BL, Brennan TP, et al.: The HBV drug entecavir-effects on HIV-1 replication and resistance. N Engl J Med 2007, 356:2614-2621.
17. Jain MK, Zoellner CL: Entecavir can select for M184V of HIV-1: a case of an HIV/hepatitis B (HBV) naive patient treated for chronic HBV. AIDS 2007, 21:2365-2366.
18. Wei X, Liang C, Gotte M, Wainberg MA: The M184V mutation in HIV-1 reverse transcriptase reduces the restoration of wild-type replication by attenuated viruses. AIDS 2002, 16:2391-2398.
19. Mohamadnejad M, Montazeri G, Fazlollahi A, et al.: Noninvasive markers of liver fibrosis and inflammation in chronic hepatitis B-virus related liver disease. Am J Gastroenterol 2006, 101:2537-2545.
20. Brook MG, Chan G, Yap I, et al.: Randomised controlled trial of lymphoblastoid interferon alfa in Europid men with chronic hepatitis B virus infection. BMJ 1989, 299:652-656.
21. Benhamou Y, Katlama C, Lunel F, et al.: Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann Intern Med 1996, 125:705-712.
22. Dore GJ, Cooper DA, Barrett C, et al.: Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. J Infect Dis 1999, 180:607-613.
23. Matthews GV, Bartholomeusz A, Locarnini S, et al.: Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS 2006, 20:863-870.
24. Bessesen M, Ives D, Condreay L, et al.: Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 1999, 28:1032-1035.
25. Pillay D, Cane PA, Ratcliffe D, et al.: Evolution of lamivudine-resistant hepatitis B virus and HIV-1 in co-infected individuals: an analysis of the CAESAR study. CAESAR co-ordinating committee. AIDS 2000, 14:1111-1116.
26. Raffi F, Snow A, Borroto-Esoda K, et al.: Anti-HBV activity of emtricitabine (ETC) in patients co-infected with HIV and hepatitis B virus [oral presentation]. Presented at the 2nd International AIDS Conference on Pathogenesis and Treatment. Paris, France; July 13-16, 2003.
27. Benhamou Y, Thibault V, Vig P, et al.: Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. J Hepatol 2006, 44:62-67.
28. Karatayli E, Karayalcin S, Karaaslan H, et al.: A novel mutation pattern emerging during lamivudine treatment shows cross-resistance to adefovir dipivoxil treatment. Antivir Ther 2007, 12:761-768.
29. Tan J, Degertekin B, Wong SN, et al.: Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovirresistant mutations. J Hepatol 2008, 48:391-398.
30. Benhamou Y, Tubiana R, Thibault V: Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus. N Engl J Med 2003, 348:177-178.
31. van Bommel F, Wunsche T, Schurmann D, Berg T. Tenofo vir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication. Hepatology 2002, 36:507-508.
32. van Bommel F, Zollner B, Sarrazin C, et al.: Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 2006, 44:318-325.
33. Peters MG, Andersen J, Lynch P, et al.: Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology 2006, 44:1110-1116.
34. Sheldon J, Camino N, Rodes B, et al.: Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 2005, 10:727-734.
35. Chang TT, Lai CL: Hepatitis B virus with primary resistance to adefovir. N Engl J Med 2006, 355:322-323; author reply 323.
36. Sherman M, Yurdaydin C, Sollano J, et al.: Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006, 130:2039-2049.
37. Tenney DJ, Levine SM, Rose RE, et al.: Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 2004, 48:3498-3507.
38. Chan HL, Heathcote EJ, Marcellin P, et al.: Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med 2007, 147:745-754.
39. Lai CL, Leung N, Teo EK, et al.: A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005, 129:528-536.
40. Dore GJ, Cooper DA, Pozniak AL, et al.: Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 2004, 189:1185-1192.
41. Gaglio PJ, Sterling R, Daniels E, Tedaldi E: Hepatitis B virus and HIV coinfection: results of a survey on treatment practices and recommendations for therapy. Clin Infect Dis 2007, 45:618-623.
42. Jain MK, Opio CK, Osuagwu CC, et al.: Do HIV care providers appropriately manage hepatitis B in coinfected patients treated with antiretroviral therapy? Clin Infect Dis 2007, 44:996-1000.
43. McGovern BH, Golan Y, Lopez M, et al.: The impact of cirrhosis on CD4+ T cell counts in HIV-seronegative patients. Clin Infect Dis 2007, 44:431-437.
44. Roland ME, Barin B, Carlson L, et al.: HIV-infected liver and kidney transplant recipients: I- and 3-year outcomes. Am J Transplant 2008, 8:355-365.
45. Lee WM: Hepatitis B virus infection. N Engl. J Med 1997, 337:1733-1745.
46. Reisler RB, Han C, Burman WJ, et al.: Grade 4 events are as important as AIDS events in the era of HAART. J Acquir Immune Defic Syndr 2003, 34:379-386.
47. Rouanet I, Peyriere H, Mauboussin JM, et al.: Acute clinical hepatitis by immune restoration in a human immunodeficiency virus/hepatitis B virus co-infected patient receiving antiretroviral therapy. Eur J Gastroenterol Hepatol 2003, 15:95-97.
48. Nuesch R, Ananworanich J, Srasuebkul P, et al.: Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection. AIDS 2008, 22:152-154.
49. Drake A, Mijch A, Sasadeusz J: Immune reconstitution hepatitis in HIV and hepatitis B coinfection, despite lamivudine therapy as part of HAART. Clin Infect Dis 2004, 39:129-132.
50. Jain MK, Parekh NK, Hester J, Lee WM: Aminotransferase elevation in HIV/hepatitis B virus co-infected patients treated with two active hepatitis B virus drugs. AIDS Patient Care STDS 2006, 20:817-822.